Table 8.
Patients sorted in descending order by absolute value of the difference between V(prescription) for the clinical target volume (CTV) obtained by using lung, heart, cord (LHC) for deformation and V(prescription) for the CTV obtained by using lung, heart, cord, external contour (LHCE) for lung deformation
| Patient | CTV V(prescription) difference | Tumor site | Disease stage | Prescription dose and fractionation scheme | Hypofx? |
|---|---|---|---|---|---|
| 10 | % | Squamous mid‐esophagus | T3N1M0 | 50.4 Gy, 28 fractions | No |
| 6 | % | NSCLC LUL | T1N0M0 | 50 Gy, 4 fractions | Yes |
| 8 | % | Adenocarcinoma RUL | T1N1M0 recurrent | 63 Gy, 30 fractions | No |
| 5 | % | NSCLC LUL | T1N2M0 | 63 Gy, 35 fractions | No |
| 9 | % | NSCLC RUL | T1N2M1 | 60 Gy, 30 fractions | No |
| 7 | % | Squamous cell carcinoma RLL | T2N2M0 | 63 Gy, 35 fractions | No |
| 2 | 0.60% | NSCLC RLL (post surgery) | T2M2N0 | 50.4 Gy, 28 fractions | No |
| 3 | % | Adenocarcinoma, distal esophagus | T3N1M0 | 50.4 Gy, 28 fractions | No |
| 1 | 0.00% | NSCLC left lung | T3N2M1 | 60 Gy, 20 fractions | No |
| 4 | 0.00% | NSCLC RUL | T1N0M0 | 70 Gy, 35 fractions | No |
; ; ; ; .